Drugs / Elemene
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05842746 | May 2023 → Dec 2026 expected | IDH-wildtype glioblastoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04674527 | Jun 2021 → Jun 2023 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04401059 | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03167775 | Nov 2016 → May 2019 | liver cancer | BeiJing Yijiayi Medicine Techonoloy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03166553 | Nov 2016 → May 2019 | liver cancer | BeiJing Yijiayi Medicine Techonoloy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elemene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05842746 ↗ |
| Action | Inhibit | “Elemene could inhibit GBM cell proliferation” NCT05842746 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “isolated from the Chinese medicinal herb Rhizoma Zedoariae” NCT04401059 ↗ |
| Route | Oral | “Elemene Oral Emulsion” NCT03166553 ↗ |